title: Allogeneic stem cell transplantation after reduced-intensity conditioning in lymphoid malignancies.
abstract: Allogeneic stem cell transplantation (allo-SCT) is an effective therapeutic option for a wide range of hematological malignancies. The toxicity of the conditioning regimen and graft-versus-host disease (GVHD) occurring after the infusion of the graft remain the most important factors leading to high morbidity and mortality. Reduced-intensity conditioning regimens have recently been developed in an effort to reduce the toxicity associated with conventional allo-SCT while preserving the curative potential of the graft-versus-tumor (GVT) effect. Most patients with lymphoproliferative disorders are not ideal candidates for allo-SCT due to higher age at diagnosis, which together with the advanced stage of disease at the time of transplantation can lead to a high transplant-related mortality (TRM). Preliminary experience indicates that reduced-intensity allo-SCT is feasible in such patients. The immediate TRM is low in comparison with conventional procedures and overall results seem promising, thus indicating the existence of a GVT effect. Nevertheless, all series are still low in numbers and follow-up is too short to draw definitive conclusions. Acute and chronic GVHD remain a significant problem with incidences comparable to the conventional setting in some series. Thus, therapeutic strategies must be sought to decrease GVHD without abrogating the GVT effect.
authors.affiliation: Clinical Hematology Division, Hospital de la Santa Creu i Sant Pau, Antoni Maria i Claret 167, 08025, Barcelona, Spain. asureda@hsp.santpau.es
authors.forename: A
authors.initials: A
authors.lastname: Sureda
authors.forename: N
authors.initials: N
authors.lastname: Schmitz
mesh_terms: D006086:Graft vs Host Disease; D020350:Graft vs Tumor Effect; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D006801:Humans; D008232:Lymphoproliferative Disorders / Q000150:complications / Q000628:therapy*; D019172:Transplantation Conditioning / Q000009:adverse effects / Q000379:methods* / Q000401:mortality; D014184:Transplantation, Homologous / Q000009:adverse effects / Q000379:methods / Q000401:mortality; D016896:Treatment Outcome